Janus Henderson Group PLC Sells 8,837 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Janus Henderson Group PLC cut its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 7.8% during the 1st quarter, HoldingsChannel.com reports. The fund owned 103,992 shares of the biopharmaceutical company’s stock after selling 8,837 shares during the period. Janus Henderson Group PLC’s holdings in Regeneron Pharmaceuticals were worth $100,085,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in REGN. Nordea Investment Management AB lifted its holdings in shares of Regeneron Pharmaceuticals by 23.2% during the 1st quarter. Nordea Investment Management AB now owns 29,195 shares of the biopharmaceutical company’s stock valued at $28,218,000 after purchasing an additional 5,495 shares in the last quarter. Sierra Summit Advisors LLC acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter worth approximately $1,011,000. Susquehanna Fundamental Investments LLC bought a new position in Regeneron Pharmaceuticals in the first quarter valued at approximately $1,232,000. Sei Investments Co. boosted its holdings in shares of Regeneron Pharmaceuticals by 8.1% in the first quarter. Sei Investments Co. now owns 24,407 shares of the biopharmaceutical company’s stock valued at $23,487,000 after buying an additional 1,839 shares during the period. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth $749,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Trading Up 0.6 %

Shares of NASDAQ:REGN traded up $6.15 during midday trading on Wednesday, reaching $1,083.95. The company’s stock had a trading volume of 75,113 shares, compared to its average volume of 463,314. The firm has a 50 day moving average price of $1,037.32 and a two-hundred day moving average price of $979.96. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $726.11 and a fifty-two week high of $1,106.16. The firm has a market capitalization of $119.44 billion, a price-to-earnings ratio of 31.75, a PEG ratio of 2.22 and a beta of 0.13. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.27.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. The business had revenue of $3.15 billion for the quarter, compared to the consensus estimate of $3.19 billion. As a group, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.36 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Michael S. Brown sold 1,172 shares of the stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $974.86, for a total transaction of $1,142,535.92. Following the transaction, the director now owns 1,382 shares of the company’s stock, valued at approximately $1,347,256.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Regeneron Pharmaceuticals news, EVP Joseph J. Larosa sold 1,866 shares of the firm’s stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $1,088.95, for a total value of $2,031,980.70. Following the transaction, the executive vice president now directly owns 37,937 shares of the company’s stock, valued at $41,311,496.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Michael S. Brown sold 1,172 shares of Regeneron Pharmaceuticals stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $974.86, for a total value of $1,142,535.92. Following the transaction, the director now owns 1,382 shares of the company’s stock, valued at approximately $1,347,256.52. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 65,074 shares of company stock worth $64,546,123. 7.48% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on REGN. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 30th. Truist Financial reiterated a “buy” rating and set a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. Royal Bank of Canada restated an “outperform” rating and issued a $1,229.00 target price on shares of Regeneron Pharmaceuticals in a research note on Monday, June 24th. Cantor Fitzgerald upped their price target on Regeneron Pharmaceuticals from $925.00 to $1,000.00 and gave the stock a “neutral” rating in a research report on Monday, July 22nd. Finally, JPMorgan Chase & Co. raised their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $1,150.00 and gave the stock an “overweight” rating in a research note on Monday, June 17th. One analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $1,074.95.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.